Beijing Health-Biotech Group (H&B for short)， established in 2007, is a Chinese government affirmed high-tech company. Its subsidiaries scattered around Beijing, Tianjin, Hebei, Guangdong, Shandong, Henan, Shanxi, Jiangxi, Fujian, Guizhou, Yunnan, Zhejiang, etc. It also setup the first overseas branch in France in 2015. Till now, H&B owns 18 subsidiaries, including Tianjin Amcellgene Engineering Co., Ltd, the Cell Products of National Engineering Research Center affirmed by National Development and Reform Commission.
As the pioneer of stem cells industry, H&B is devoted to the development of stem cells related products which are compliant to clinical standards, widely sourced, easily collected, convenient for quality control, and without ethical disputes. It’s capable of conducting stem cells product research, preparation and application and providing stem cells related technical service. Since 1990’s, the research team led by Professor Zhongchao Han has initiated three renovations to perinatal stem cells technology.
The Cord blood hemopoietic stem cell bank established in 1999 is one of the few mature cord blood stem cell banks in the world.
After listing of the blood derived stem cell company, the research team lead by Professor Zhongchao Han start to develop umbilical derived stem cells. Tianjin Amcellgene Mesenchymal Stem cell bank, setup in 2005, is now a leading umbilical stem cell bank in the world. The related products are widely used in clinical trials.
After years research, H&B research team developed a technology to extract the most precious placenta derived stem cells in 2009 and established a stem cell bank that can preserve four kinds of placenta derived stem cells simultaneously.
Nowadays, H&B stem cells industrialization platform owns the second generation (umbilical derived) and third generation (placenta derived) perinatal stem cell technology. To better develop stem cell product, H&B has set up Stem cell Institute and Health Technology Popularization Company. Moreover, it sets up stem cell banks in most provinces, preserving stem cells for future use.
Till now, H&B has developed from a single stem cell bank into a comprehensive enterprise covering the fields of stem cell banking, stem cells technology application, stem cells drug development, tissue engineering and skin care.